Company intelligence / Profile preview
Ardeypharm
- Ownership
- Private
- Development stage
- Other
Overview
Ardeypharm specializes in the development, manufacturing, and commercialization of probiotic drugs—most notably Mutaflor®, which contains the unique non-pathogenic Escherichia coli strain Nissle 1917. The company also offers a range of chemically defined pharmaceuticals and herbal remedies targeting gastrointestinal health. Their R&D has a strong focus on the human intestinal microbiota's role in health, with collaborations involving hospitals and universities worldwide. Their lead probiotic drug has established clinical evidence supporting its use in various GI conditions.[1][2][4]
- Therapeutic areas
- GastroenterologyMetabolic DisordersInfectious Diseases
- Modalities
- Live biotherapeutic product therapySmall moleculeHerbal remedy
- Industry
- Biotech
Drug pipeline
7 assets6 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Ardeypharm.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ardeypharm.